Abstract:<bold>Background</bold>: The ratio of fibrinogen to gamma-glutamine transferase (FGR) was used to predict long-term prognosis in patients with coronary heart disease (CHD). <bold>Methods</bold>: A total of 5638 patients with CHD who were hospitalized from January 2008 to December 2016 were retrospectively enrolled in the study. The mean follow-up time was 35.9 +/-+/- 22.5 months. The follow-up endpoints were major cardiac and cerebrovascular adverse events (MACCE). The optimal FGR cut-off value was determined and divided into high- and low-FGR groups according to the receiver operating characteristic (ROC) curve. Statistical methods were used to compare the differences between the two groups and their prognoses to determine whether FGR can predict prognosis in patients with CHD. The traditional predictors were incorporated into the logistic regression model to observe the correlation between these indicators and all-cause mortality (ACM) events. We compared the prediction performance of FGR and traditional predictors on the occurrence of ACM events by ROC curves. <bold>Results</bold>: The optimal cut-off value was determined via a ROC analysis (FGR = 1.22, p = 0.002), and subjects were classified into high and low FGR groups. The follow-up found that the incidence of MACCE in the high FGR group was higher than that in the low FGR group. The COX multivariate regression model showed that high FGR was independently correlated with the occurrence of MACCE. In addition, the Kaplan-Meier survival curve showed that the risk of events was significantly increased in the group with high FGR. With increases in the FGR ratio, the risk of MACCE was increased. The ROC curve revealed that the risk of ACM was statistically different between the FGR and the traditional risk factor model (p = 0.002), (Fibrinogen (p = 0.008), gamma-glutamine transferase (GGT) (p = 0.004), and N-terminal pro brain natriuretic peptide (NT-ProBNP) (p = 0.024)). The comparison between other different models were not statistically significant (p >> 0.05). The area under the FGR model curve was larger than that of the traditional risk factors, fibrinogen, GGT and NT-ProBNP models. <bold>Conclusions</bold>: High FGR can increase the risk of MACCE in patients with CHD; additionally, it can be used as a new biomarker for long-term prognosis in CHD patients.

The Research Progress of γ-Glutamyl Transferase in Coronary Heart Disease

[Plasma Gamma-Glutamyl Transpeptidase Level As a Cardiovascular Risk Factor in Elderly Patients with Hypertension or Hypertension with Diabetes Mellitus].

Tumor and Serum Gamma-Glutamyl Transpeptidase, New Prognostic and Molecular Interpretation of an Old Biomarker in Gastric Cancer

GSTM2 Alleviates Heart Failure by Inhibiting DNA Damage in Cardiomyocytes.

Moderate Serum Γ-Glutamyl Transferase Level is Beneficial for Heart Failure after Percutaneous Coronary Intervention.

Association between serum γ-glutamyltransferase levels and coronary microvascular function

Recent Advances in the Development of Optical Imaging Probes for Γ-Glutamyltranspeptidase.

Elevated serum gamma-glutamyltransferase predicts advanced histological liver damage in chronic hepatitis B.

Predictive Value of the Fibrinogen to Gamma-Glutamine Transferase Ratio in the Long-Term Outcome in Patients with Coronary Heart Disease: A Retrospective Cohort Study

Γ-Glutamyltranspeptidase is a Prognostic Marker of Survival and Recurrence in Radiofrequency-Ablation Treatment of Hepatocellular Carcinoma.

Integrated Metabolomics and Metagenomics Analysis of Plasma and Urine Identified Microbial Metabolites Associated with Coronary Heart Disease

Correlation of Plasma Gamma-Glutamyltransferase and Blood Pressure

A near-infrared fluorescent probe for evaluating glutamyl transpeptidase fluctuation in idiopathic pulmonary fibrosis cell and mice models

Constructing a novel fluorescence detection method for γ-glutamyltranspeptidase and application on visualizing liver injury

γ-Glutamyltranspeptidase as a Prognostic Biomarker in Advanced Hepatocellular Carcinoma Treated with Transarterial Chemoembolization

Roles and potential clinical implications of tissue transglutaminase in cardiovascular diseases

Multifunctional fluorescence/photoacoustic bimodal imaging of γ -glutamyltranspeptidase in liver disorders under different triggering conditions

Therapeutic Effect of Hepatocyte Growth Factor on Coronary Heart Disease

γ-Gammaglutamyl transferase predicts all-cause mortality within three-year intervals in patients undergoing peritoneal dialysis

Effect of γ-glutamyl transpeptidase on Ito channel remodeling in rat heart post-myocardial infarction

Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization.